Advocacy services for adults with health and social care needs
In development [GID-NG10156] Expected publication date: 09 November 2022
Search results
477 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development [GID-DG10038] Expected publication date: TBC
-
Transperineal biopsy for diagnosing prostate cancer
In development [GID-DG10043] Expected publication date: TBC
-
Genedrive MT-RNR1 ID System for detecting single nucleotide polymorphism m.1555A G in newborn babies (provisional title)
In development [GID-DG10057] Expected publication date: 13 September 2023
-
Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain
In development [GID-DG10036] Expected publication date: 15 November 2023
-
Automated ankle brachial pressure index measurement devices for assessing peripheral arterial disease in people with leg ulceration
In development [GID-DG10049] Expected publication date: 12 April 2023
-
Software with artificial intelligence derived algorithms for automated detection and analysis of lung nodules from CT scan images
In development [GID-DG10046] Expected publication date: 28 June 2023
-
MRI fusion biopsy in people with suspected prostate cancer
In development [GID-DG10050] Expected publication date: 17 May 2023
-
Clopidogrel genotype testing after ischaemic stroke (provisional title)
In development [GID-DG10054] Expected publication date: 16 August 2023
-
Devices for remote continuous monitoring of people with Parkinson's disease
In development [GID-DG10047] Expected publication date: 25 January 2023
-
MRI-based technologies for assessing non-alcoholic fatty liver disease
In development [GID-DG10045] Expected publication date: 26 October 2022
-
Artificial intelligence (AI) software to help clinical decision making in stroke
In development [GID-DG10044] Expected publication date: TBC
-
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease (CAD) (provisional title)
In development [GID-DG10062] Expected publication date: 16 February 2023
-
KardiaMobile 6L for measuring QT interval in people having antipsychotic medication
In development [GID-DG10048] Expected publication date: 07 October 2022
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: 19 October 2022
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
In development [GID-TA10446] Expected publication date: TBC
-
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]
In development [GID-TA10445] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503
In development [GID-TA10401] Expected publication date: TBC
-
Asunercept for treating glioblastoma [1301]
In development [GID-TA10227] Expected publication date: TBC
-
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
In development [GID-TA10225] Expected publication date: TBC
-
Selumetinib for treating differentiated thyroid cancer ID1079
In development [GID-TA10207] Expected publication date: TBC
-
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development [GID-TA10249] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal [TA714] Published: 14 July 2021
-
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal [TA560] Published: 20 February 2019
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published: 24 May 2019
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
In development [GID-TA10764] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC